Reata Pharmaceuticals (RETA) PT Raised to $51 at Citi on Potential Omav Approval

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. XYZ
8. SWKS
9. FISV
10. CVS

Go back to Reata Pharmaceuticals (RETA) PT Raised to $51 at Citi on Potential Omav Approval

Reata Pharma (RETA) Climbs 12% After Announcing FDA Does Not Plan to Hold AdCom for Omaveloxolone for Friedreich’s Ataxia

October 13, 2022 4:40 PM EDT

Reata Pharma (NASDAQ: RETA) Climbs 12% After Announcing FDA Does Not Plan to Hold AdCom for Omaveloxolone for Friedreichs Ataxia

... More

Reata Pharma (RETA) Announces FDA Does Not Plan to Hold AdCom for Omaveloxolone for Friedreich’s Ataxia

October 13, 2022 4:38 PM EDT

Reata Pharmaceuticals,... More